XBiotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-24.56	-32.9	-17.41	-11.22	668.63	-21.14	-33.15	-52.76	-37.48	-21.72	Upgrade
Depreciation & Amortization	1.74	2.61	2.65	2.24	2.36	2.43	1.48	0.7	0.7	0.66	Upgrade
Share-Based Compensation	3.26	5.06	4.46	12.58	3.36	1.66	1.75	5.57	4.41	7.02	Upgrade
Other Operating Activities	0.83	10.4	79.75	-68.75	-692.62	0.51	-3.73	0.48	-0.93	2.34	Upgrade
Operating Cash Flow	-18.73	-14.82	69.45	-65.15	-18.27	-16.54	-33.65	-46.02	-33.31	-11.7	Upgrade
Capital Expenditures	-0.36	-0.59	-3.53	-3.73	-0.2	-0.12	-1.41	-13.91	-10.39	-1.4	Upgrade
Acquisitions	0	0	0	0	675	0	0	0	0	0	Upgrade
Change in Investments	61.86	-63.31	0	0	0	0	0	0	0	0	Upgrade
Investing Cash Flow	61.5	-63.89	-3.53	-3.73	674.8	-0.12	-1.41	-13.91	-10.39	-1.4	Upgrade
Dividends Paid	0	0	-75	0	0	0	0	0	0	0	Upgrade
Share Issuance / Repurchase	-0.01	0	8	-409.72	42.1	0.2	33.32	2.94	77.47	63.52	Upgrade
Other Financing Activities	-	-	-	-	-	-	-	-	-	-0.32	Upgrade
Financing Cash Flow	-0.01	0	-67.01	-409.72	42.1	0.2	33.32	2.94	77.47	63.2	Upgrade
Exchange Rate Effect	-0.05	-0.96	0.71	1.37	0.15	0.51	-0.83	0.26	-0.05	-0.02	Upgrade
Net Cash Flow	42.72	-79.68	-0.38	-477.23	698.77	-15.95	-2.56	-56.73	33.72	50.09	Upgrade
Free Cash Flow	-19.09	-15.41	65.92	-68.88	-18.47	-16.66	-35.05	-59.93	-43.7	-13.1	Upgrade
Free Cash Flow Margin	-	-384.26%	358.38%	-156.55%	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.63	-0.51	2.19	-2.23	-0.47	-0.47	-1.00	-1.85	-1.42	-0.54	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).